Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors;Concentraciones séricas preoperatorias de antígeno carbohidrato 15.3 y antígeno carcinoembrionario y características clínico-biológicas tisulares de los carcinomas mamarios

Revista Espanola de Medicina Nuclear

Volumn 25, Issue 3, 2006, Pages 180-183

  Ruibal, A ^a   Garrido Pumar, M ^a   Arias, J I ^b  

^a University Hospital of Santiago de Compostela   (Spain)

^b Hospital Monte del Naranco   (Spain)

Author keywords

Breast cancer; CA15.3; CEA; Tissue clinical biological parameters

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HYALURONIC ACID; PROTEIN PS2; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD ANALYSIS; BREAST CARCINOMA; BREAST TUMOR; CANCER GRADING; CANCER INFILTRATION; CELL COMPOSITION; CELL CYCLE S PHASE; CELL SURFACE; CONTROLLED STUDY; CYTOSOL; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PARAMETER; PREOPERATIVE EVALUATION; TUMOR VOLUME;

EID: 33745644046     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13088414     Document Type: Article

References (11)

1. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny Gem Schmitt UM, Fateh-Moghadam A, et al. Serum CEA and CA 15.3 as prognostic factors in primary breast cancer. Br J Cancer. 2002;86:1217-22.
2. Nakamura T, Kimura T, Umehara Y, Suzuki K, Okamoto K, Okumura T, et al. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15.3 levels as postoperative surveillance alter breast cancer surgery. Surg Today. 2005;35:19-21.
3. Ruibal A, Arias JI, Del Rio MC, Lapena G, Schneider J, Tejerina A. Histological grade in breast cancer: association with clinical and biological features in a series of 229 patients. Int J Biol Markers. 2001;16:56-61.
4. Ruibal A, Genolla J, Rosell M, Gris JM, Colomer R. Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients. Int J Biol Markers. 1986;1:159-60.
5. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA15.3, TNM staging, estrogen receptor rate and MINI-1 index in patients with pTl-2 breast cancer. Anticancer Res. 2004;24:3221-4.
6. Shering SG, Sherry F, McDermott EW, O'Higgins NJ, Duffy MJ. Preoperative CA15.3 concentrations predict outcome of patients with breast carcinoma. Cancer. 1998;83:2521-7.
7. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, et al. Prospective evaluation of tumor markers (c-erbB2 oncoprotein, CEA and CA15.3) in patients with locoregional breast cancer. Anticancer Res. 2003;23:1043-50.
8. Seker D, Kaya O, Adabag A, Necipoglu G, Baran I. Role of preoperative plasma CA15.3 and carcinoembryonic antigen levels in determining histopathologic conventional prognostic factors for breast cancer. World J Surg. 2003;27:519-21.
9. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, et al. Elevated serum CA15.3 levels correlate with positive estrogen receptor and initial favourable outcome in patients who died from recurrent breast cancer. Breast Cancer. 2003;10:220-7.
10. Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E, Crown J, et al.: High preoperative CA15.3 concentrations predict adverse outcome in node-negative and node positive breast cancer: study of 600 patients with histopathologically confirmed breast cancer. Clin Chem. 2004;50:559-63.
11. Gion M, Mione R, Dittadi R, Fasan S, Pallini A, Bruscagnin G: Carcinoembryonic antigen, ferritin and tissue polypeptide antigen in serum and tissue. Relationship with the receptor content in breast carcinoma. Cancer. 1986;57:917-22.